530 related articles for article (PubMed ID: 20032442)
21. ProGRP: a new biomarker for small cell lung cancer.
Molina R; Filella X; Augé JM
Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231
[TBL] [Abstract][Full Text] [Related]
22. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
[No Abstract] [Full Text] [Related]
23. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
[TBL] [Abstract][Full Text] [Related]
24. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
Bubanović G; Pavićević R; Franjević A
Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
[TBL] [Abstract][Full Text] [Related]
25. [The value of plasma pro-gastrin-releasing peptide, cytokeratin 19-fragments and carcinoembryonic antigen in patients with lung cancer].
Chen YJ; Jin WD; Yang GY; Zhou YL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):381-3. PubMed ID: 22338231
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
[TBL] [Abstract][Full Text] [Related]
27. Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid.
Kakari S; Stringou E; Toumbis M; Ferderigos AS; Poulaki E; Chondros K; Dema A; Kotsovoulou V; Pavlidis N
Anticancer Res; 1991; 11(6):2107-10. PubMed ID: 1663720
[TBL] [Abstract][Full Text] [Related]
28. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer.
Huang Z; Xu D; Zhang F; Ying Y; Song L
Clin Transl Oncol; 2016 Oct; 18(10):1019-25. PubMed ID: 26886220
[TBL] [Abstract][Full Text] [Related]
29. [Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival].
Załeska M; Szturmowicz M; Zych J; Roszkowska-Sliz B; Demkow U; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2010; 78(1):14-20. PubMed ID: 20162514
[TBL] [Abstract][Full Text] [Related]
30. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
31. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
32. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
33. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
34. Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer.
Wojcik E; Tarapacz J; Rychlik U; Stasik Z; Sas-Korczynska B; Skotnicki P; Kulpa JK
Clin Lab; 2016 Sep; 62(9):1625-1632. PubMed ID: 28164590
[TBL] [Abstract][Full Text] [Related]
35. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
36. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.
Molina R; Marrades RM; Augé JM; Escudero JM; Viñolas N; Reguart N; Ramirez J; Filella X; Molins L; Agustí A
Am J Respir Crit Care Med; 2016 Feb; 193(4):427-37. PubMed ID: 26465739
[TBL] [Abstract][Full Text] [Related]
37. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
[TBL] [Abstract][Full Text] [Related]
38. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
39. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
40. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer.
Bi H; Yin L; Fang W; Song S; Wu S; Shen J
Lab Med; 2023 Jul; 54(4):372-379. PubMed ID: 36282321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]